

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai MicroPort MedBot (Group) Co., Ltd.**

**上海微创医疗机器人(集团)股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2252)**

## **VOLUNTARY ANNOUNCEMENT – TOUMAI HAS RECEIVED OVER 300 COMMERCIAL ORDERS WORLDWIDE**

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “Company”, together with its subsidiaries, the “Group”) on a voluntary basis.

**The board of directors of the Company (the “Board”) is pleased to announce that, based on the Company’s preliminary internal statistical data, as of the date of this announcement, the cumulative order volume of the Group’s core products across laparoscopic, orthopedic and vascular intervention specialties has amounted to almost 400 units. Among these, the Group’s core product, the Toumai® (圖邁®) Laparoscopic Surgical Robot (“Toumai”), has received over 300 commercial orders worldwide, with new orders secured in the first half of the year having already surpassed the total for the whole of the previous year, marking yet another milestone breakthrough in the commercial orders of Toumai. Looking back on Toumai’s commercialisation journey: the first hundred orders took nearly 1,000 days of product refinement and market cultivation, whereas now the third hundred orders have been achieved in just over 120 days, fully demonstrating the comprehensive maturity of Toumai’s product competitiveness, brand recognition, and overseas channel deployment capabilities, with business expansion entering a fast track.**

**Toumai continues to accelerate its global multi-regional presence rapidly. To date, it has achieved commercial installations in more than 60 countries and regions. Benefiting from scaled commercial installations and the technological leadership in remote surgery, Toumai’s brand influence has ranked among the top two globally. Since the beginning of this year, Toumai has newly entered over ten countries or markets, including Saudi Arabia and South Korea, and has obtained market access in over 40 additional countries awaiting progressive implementation. Toumai continued to maintain strong growth momentum in the emerging markets, with cumulative orders exceeding 30 units in India and nearly 20 units in the Brazilian and Argentine markets, respectively. The Board is of the view that the rapid accumulation of the aforesaid orders will help consolidate the Group’s future revenue base and have a positive impact on the Group’s operating performance for the year 2026.**

**To date, Toumai has facilitated over half of all laparoscopic surgical robot remote surgeries performed worldwide, covering nearly 30 countries, with a continued 100% implementation success rate. The Toumai Remote Surgical Robotics has been approved for marketing in nearly 20 countries.** Since the beginning of 2026, Toumai has successively assisted experts from China, the United Kingdom, Brazil, Thailand, India and other countries in performing inter-provincial, cross-border and intercontinental remote robotic surgeries, covering complex and high-difficulty procedures across multiple clinical specialties, including cardiac surgery, urology, general surgery, thoracic surgery and gynaecology. The longest surgical distance reached 18,900 kilometres, representing a truly “half-the-globe” remote surgical collaboration. Most recently, Toumai assisted a renowned international robotic surgery expert in successfully performing the world’s first robot remote surgery based on the Starlink low-earth orbit satellite communication network. Ranging from dedicated network lines and 5G networks to standard broadband, and further to space-air-ground integrated satellite communication networks, Toumai is continuously driving remote surgery towards “low cost, broad coverage, strong connectivity and high accessibility”, leading remote surgery into a new era of “space-earth interconnection and unbounded medical collaboration”.

**In the AI-integration field, the Group has built a large-model technology system for autonomous robotic surgery,** established a digital surgical simulation platform, completed virtual simulations of surgical instruments and soft tissues, and integrated functions for soft-tissue deformation and fine surgical-operation simulation. Relying on large-model technology, we have built a reinforcement learning algorithmic reward system, and around surgical scene understanding, fine surgical manipulation and instrument trajectory iterative training models, we have achieved autonomous robotic surgical operations and completed animal experiment validation.

**To meet rapidly growing orders and installation demands for multiple products, the Group has established a multi-level supply chain system covering precision parts, consumables, core components and system integration, and has achieved production capacity at scale for a number of marketed surgical robots and their complementary consumables. The annual production capacity of various surgical robot products such as Toumai has exceeded 500 units.** We also continuously optimise the production and iteration efficiency of products through strategic and refined supply chain operation management. While enhancing the product delivery rate, we ensure quality improvement, efficiency enhancement and continuous cost reduction in the manufacturing process. As business scale expands and capacity utilisation gradually improves, operating leverage is expected to materialise, laying a solid foundation for further gross margin improvement.

The above information is provided by the Company on a voluntary basis to provide the shareholders of the Company (the “**Shareholders**”) and potential investors with the update on the latest business development of the Group.

The Board wishes to remind Shareholders and potential investors that the above information is unaudited and based on preliminary internal information of the Group, which may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company on an annual or half-yearly basis due to various uncertainties during the process of collating such information.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Shanghai MicroPort MedBot (Group) Co., Ltd.**  
**Dr. Zhaohua Chang**  
*Chairman*

Shanghai, China, 16 June 2026

*As at the date of this announcement, the executive Directors are Dr. Chao He and Mr. Yu Liu, the non executive Directors are Dr. Zhaohua Chang, Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Mr. Chen Chen and Ms. Min Liang, and the independent non-executive Directors are Dr. Guoen Liu, Mr. Jonathan H. Chou, Mr. Haisong Yao and Mr. Wai Man Chung.*